Fosamax (alendronate) is now approved for treating osteoporosis in men or women taking chronic glucocorticoids

Fosamax (alendronate) is now approved for treating osteoporosis in men or women taking chronic glucocorticoids.

This new indication is for patients who take the equivalent of 7.5 mg/day or more of prednisone...AND have low bone mineral density.

These patients can lose up to 15% of their overall bone mass in their first year on steroids. Fractures occur in up to 50% of people on long-term steroids.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote